SUMMARY We studied 11 patients with congestive heart failure and 10 normal volunteers for in vivo platelet aggregate formation activity. The patients with heart failure had significantly (p < 0.01) more circulating platelet aggregates than the normal volunteers. During sodium nitroprusside infusion, the number of circulating platelet aggregates declined to normal levels and in vitro platelet aggregation responses to epinephrine and adenosine diphosphate were also suppressed significantly (p < 0.01). This was associated with a 30% decline in systemic vascular resistance and a 28% increase in cardiac output. In other in vitro experiments, sodium nitroprusside was found to have direct, dose-related platelet aggregation inhibitory actions. This study suggests that an increase in vascular resistance in certain heart failure patients may in part be related to an increase in circulating platelet aggregates.
PATIENTS WITH VASCULAR insufficiency have been shown to have increased in vivo platelet aggregate formation activity' 2 and increased in vitro platelet aggregation in response to epinephrine and ADP.3' I Several investigators have suggested that the occlusion of small vessels by platelet aggregates may be responsible for tissue ischemia, injury and death.5-9 Most patients with congestive heart failure have increased vascular resistance as either a primary or a secondary event.'0 11 Whether platelet aggregate formation activity is in any way related to the increase in vascular resistance in these patients is not known. The use of vascular resistance-lowering agents like nitroprusside has been beneficial in the treatment of patients with heart failure.' [1] [2] [3] Sodium nitroprusside is thought to be effective by its direct dilatory actions on vascular smooth muscle,'4 resulting in decreased vascular resistance and improved cardiac function. Recently, the platelet aggregation inhibitory effects of nitroprusside have also been recognized. '5-17 This study was designed to evaluate in vivo platelet aggregate formation activity in patients with congestive heart failure. We also studied the effects of intravenous administration of nitroprusside on platelet aggregate formation.
Eleven patients (age 24-59 years, mean 48 years) who had chronic congestive heart failure, documented by clinical, roentgenologic and hemodynamic criteria, and were undergoing nitroprusside therapy, form the basis of this report. Heart failure in eight patients was due to ischemic cardiomyopathy and in three to longstanding valvular disease. Ten had been previously treated with digitalis and diuretics, and one had received only diuretic therapy. All patients were in a stable state and had no recognizable acute illness. Blood studies were also performed on 10 normal, healthy volunteers (age 22-41 years, mean 32 years) as control. None of the patients or the healthy volunteers had taken aspirin or other agents known to alter platelet function in the preceding 2 weeks.
Hemodynamic Studies in Heart Failure Patients
After an informed consent detailing the procedure was obtained, a triple-lumen, flow-directed catheter was positioned in the pulmonary artery to measure pulmonary artery and wedge pressures and cardiac output. An arterial cannula was also inserted in the brachial artery to record the systemic pressure. The details of the hemodynamic measurements have been previously reported.12 After control hemodynamics were recorded, a nitroprusside infusion was started at 10 ,ug/min. The dose was gradually increased in 10-,g/min increments every 10 minutes until a significant change in hemodynamics (a reduction in pulmonary wedge pressure to 15 mm Hg or a 50% increase in cardiac output or a decline in the systolic blood pressure to 100 mm Hg) occurred. The nitroprusside infusion was then gradually discontinued. lected once from all but three of the normal volunteers, from whom blood was collected twice at a 1-hour interval for validation of platelet studies.
Blood (9 ml) was collected from a previously unpunctured peripheral vein using a large-lumen needle (#18), each time by the same person and at a steady rate. The blood was immediately transferred into polypropylene tubes containing 1.0 ml of 3.8% sodium citrate. From these samples, platelet-rich plasma (PRP) was obtained by centrifugation at 150 g for 8 minutes at room temperature. The remaining blood was spun at 5,000 g for 30 minutes at room temperature to yield platelet-poor plasma (PPP). Platelet counts in PRP were adjusted at 300,000/mm3 by adding PPP as required. The platelet aggregation studies were performed in duplicate within 2 hours of blood collection, as described earlier. The method used to determine microthrombus formation activity was similar to that described by Wu and Hoak.', 7 20 Samples of exactly 0.5 ml each were withdrawn into plastic syringes containing 2.0 ml of buffered EDTA or buffered EDTA and formalin. The samples were taken in duplicate, gently tilted and allowed to stand for 15 minutes at room temperature. The four tubes were then centrifuged simultaneously at 150 g for 8 phase microscopy, and the results were expressed as follows: Microthrombus Index (MTI) = Platelet count in EDTA/formalin PRP Platelet count in EDTA PRP This method is based on the idea that platelet aggregates, when present, will be fixed in the EDTA/formalin mixture and centrifuged down. Therefore, the platelet count of the PRP solution will be reduced. However, in the syringe with EDTA alone, platelet aggregates are broken. Therefore, the ratio approaches one when there are no aggregates, but drops below one if aggregates are present. The buffered EDTA and formalin solution was prepared by adding 3.0 ml of 0.077 M EDTA, 5.0 ml of 4% formalin, and 2.0 ml of concentrated (lOX) phosphate-buffered saline solution (PBS) to 10.0 ml of distilled water. The buffered EDTA solution was prepared by adding 3.0 ml of 0.077 M EDTA and 5.0 ml of concentrated (lOX) PBS to 12.0 ml of distilled water. Both solutions were isotonic, with a pH of 7.4. All the solutions were freshly prepared before blood collection.
In Vitro Studies
Sodium nitroprusside, obtained as anhydrous powder (Roche Labs, Nutley, New Jersey), was diluted with 5% dextrose in water (D5W) to achieve different concentrations and was used within 4 hours while being protected from exposure to light. The PRP obtained from 10 normal volunteers was incubated at 37°C for 3 minutes and either 0.1 ml of D5W or 0.1 ml of D5W and nitroprusside was added. The platelet aggregation studies were performed as described above, using epinephrine, ADP 1.0, 2.0 and 4.0 gM and collagen 0.13 mg as aggregating agents.
Calculations
The average of the duplicate values from each patient and the control subjects was used for cal-FIGURE 1. A typical platelet aggregation curve after the addition of aggregating agent. The methodfor measuring the rate of aggregation for the primary wave (PApl min), the maximal extent ofaggregation for the primary wave (PAp max), and the maximal extent of total platelet aggregation (PA max) are shown. fig. 3 ). Platelet aggregation was inhibited in all subjects studied.
Microthrombus Index
During nitroprusside therapy, MTI in heart failure patients increased significantly (p < 0.001) to 0.88 ± 0.66 (range 0.41-1.20) (fig. 4 ). This increase in MTI was observed in each patient. MTI during nitroprusside therapy in heart failure patients was similar (p = NS) to that in normal volunteers. Patients with Normal Heart Failure Volunteers FIGURE 2. Platelet microthrombus index in patients with heart failure and in normal volunteers. The mean value is significantly lower in heart failure patients than in normal volunteers.
significantly inhibit epinephrine-induced platelet aggregation. The effect of larger amounts of the aggregating agent (ADP) could be blocked by larger amounts of nitroprusside. Discussion Several investigators have shown that in vivo platelet aggregate formation activity is increased in ischemic disorders such as coronary heart disease, peripheral vascular disease and cerebrovascular in- I-
